Table 2:

BerEP4 immunoreactivity in various tumors.^[22]

Immunoreactive	Non-immunoreactive
Adenocarcinomas (most, 50–100% in various studies) Neuroendocrine tumors, including small cell carcinoma Chromophobe renal cell carcinoma (75%), papillary renal cell carcinoma (55%), clear cell renal carcinoma (18%), metastatic renal cell carcinoma (14%) Hepatocellular carcinoma Basal cell carcinomas Basosquamous carcinomas Synovial sarcoma	Mesothelioma* Lymphoma Most soft-tissue sarcomas Adenomatoid tumor Renal oncocytoma

^*However, 4–26% of mesotheliomas may show BerEP4 immunoreactivity (which is usually membranous with microvillous pattern, in contrast to the cytoplasmic and membranous pattern in non-mesothelial tumors). Due to this, lack of immunoreactivity for BerEP4 favor mesotheliomas in malignant clinical setting. However, this non-immunoreactivity should be applied with an appropriate immunopanel (to discriminate mesothelioma from other metastases in serous effusions): At least two immunoreactive mesothelial immunomarkers (such as calretinin, vimentin, cytokeratin 7, and WT1) with at least two non-mesothelial immunomarkers (such as BerEP4, B72.3, and relevant lineage-specific immunomarker in particular clinical scenario such as lung primary)